Oncology · Phase 2-3 · pulled 2026-11-06

Breast cancer: trial sites and investigators

25 sites and 10 investigators from 300 completed and terminated Phase 2-3 trials of breast cancer (last 12 years), plus 300 trials recruiting now.

A cited data summary, not a recommendation to select or exclude any site. Every line links to the registry record behind it.

Sites

Sites are listed in the registry's own order: comparable trials listed (most first), ties by latest completion, then name. The Sitecite score is a second column. “Competing now” counts recruiting, active and not-yet-recruiting trials in the same indication at that site.

Breast cancer: sites in the registry's trial-count order, with the Sitecite score as a second column
#	Site	Comparable trials listed	Trials (ClinicalTrials.gov)	Latest completion	Competing now	Score (0-100)
1	MD Anderson Cancer Center Houston, United States · 22 spellings merged	30 6 completed, 24 terminated	NCT05747794 NCT05325866 NCT06408168 6 trials with titles NCT05747794 Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy terminated 2026-06-30 Stop reason on the record: “Sponsor Decision” NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT06408168 Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial) terminated 2025-12-08 Stop reason on the record: “\<75% Participation” NCT04216472 Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations terminated 2025-09-22 Stop reason on the record: “\<75% participation” NCT06171789 PRO1107 in Patients With Advanced Solid Tumors terminated 2025-08-18 Stop reason on the record: “Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation” NCT04902872 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors completed 2025-06-24	2026-06-30	59 NCT05546268 NCT06058377 NCT06324357 NCT06982521	77
2	Hospital Universitari Vall d'Hebron Barcelona, Spain · 21 spellings merged	21 13 completed, 8 terminated	NCT06604858 NCT05747794 NCT05865990 6 trials with titles NCT06604858 Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer completed 2026-07-07 NCT05747794 Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy terminated 2026-06-30 Stop reason on the record: “Sponsor Decision” NCT05865990 HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease completed 2026-04-03 NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT06188559 A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer completed 2026-03-18 NCT05963997 A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer completed 2026-03-06	2026-07-07	29 NCT06966453 NCT06393374 NCT06324357 NCT06982521	84
3	Hospital Universitario Virgen del Rocio Seville, Spain · 8 spellings merged	18 11 completed, 7 terminated	NCT05573555 NCT06604858 NCT05181462 6 trials with titles NCT05573555 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) terminated 2026-10-06 Stop reason on the record: “Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. The decision was not related to safety, efficacy, benefit-risk, or participant welfare. The pl” NCT06604858 Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer completed 2026-07-07 NCT05181462 Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. completed 2026-05-08 NCT05865990 HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease completed 2026-04-03 NCT05207709 Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype terminated 2026-03-26 Stop reason on the record: “The study was prematurely halted because enrollment was significantly delayed compared with the original projections due to the evolving therapeutic landscape.” NCT05063786 Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET) terminated 2025-12-23 Stop reason on the record: “Study prematurely terminated due to recruitment challenges, low incidence of the target population, evolving treatment landscape, ethical considerations, and inability to ensure funding through study ”	2026-10-06	15 NCT06393374 NCT07413939 NCT06492616 NCT07174336	88
4	Sarah Cannon Research Institute Nashville, United States · 24 spellings merged	16 9 completed, 7 terminated	NCT05180474 NCT05708950 NCT04224272 6 trials with titles NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT05708950 A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) completed 2025-12-18 NCT04224272 Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant completed 2025-06-30 NCT04699630 A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer completed 2025-04-09 NCT04539938 A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer completed 2025-03-07 NCT04332653 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors completed 2025-01-13	2026-03-25	33 NCT05546268 NCT03424005 NCT06966453 NCT06393374	87
5	Hospital Universitario 12 de Octubre Madrid, Spain · 7 spellings merged	15 6 completed, 9 terminated	NCT05573555 NCT05181462 NCT05207709 6 trials with titles NCT05573555 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) terminated 2026-10-06 Stop reason on the record: “Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. The decision was not related to safety, efficacy, benefit-risk, or participant welfare. The pl” NCT05181462 Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. completed 2026-05-08 NCT05207709 Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype terminated 2026-03-26 Stop reason on the record: “The study was prematurely halted because enrollment was significantly delayed compared with the original projections due to the evolving therapeutic landscape.” NCT05744375 Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab terminated 2025-07-17 Stop reason on the record: “The study stopped due to insufficient accrual (only two patients were included), and the sponsor has decided on its premature termination.” NCT06465368 A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause completed 2025-07-10 NCT05954143 Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer terminated 2024-09-25 Stop reason on the record: “Sponsor Decision”	2026-10-06	30 NCT06324357 NCT06982521 NCT07413939 NCT06492616	68
6	Memorial Sloan Kettering Cancer Center New York, United States · 14 spellings merged	14 5 completed, 9 terminated	NCT05852691 NCT06188559 NCT05007106 6 trials with titles NCT05852691 A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer completed 2026-10-15 NCT06188559 A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer completed 2026-03-18 NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT04916002 A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer terminated 2024-10-31 Stop reason on the record: “Sponsor Decision related to study drug supply” NCT05954143 Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer terminated 2024-09-25 Stop reason on the record: “Sponsor Decision” NCT05190770 A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer completed 2024-08-27	2026-10-15	30 NCT05546268 NCT06393374 NCT06324357 NCT07918989	72
7	Washington University School of Medicine St Louis, United States · 21 spellings merged	14 4 completed, 10 terminated	NCT05573555 NCT06125522 NCT04331067 6 trials with titles NCT05573555 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) terminated 2026-10-06 Stop reason on the record: “Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. The decision was not related to safety, efficacy, benefit-risk, or participant welfare. The pl” NCT06125522 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) terminated 2026-09-10 Stop reason on the record: “Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. The decision was not related to safety, efficacy, benefit-risk, or participant welfare. The pla” NCT04331067 Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer terminated 2026-06-09 Stop reason on the record: “BMS terminated the study” NCT06844669 HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy terminated 2026-05-07 Stop reason on the record: “Futility” NCT06188559 A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer completed 2026-03-18 NCT04699630 A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer completed 2025-04-09	2026-10-06	42 NCT05546268 NCT06058377 NCT06393374 NCT06982521	65
8	Hospital Clinic de Barcelona Barcelona, Spain · 13 spellings merged	14 6 completed, 8 terminated	NCT05747794 NCT05181462 NCT05207709 6 trials with titles NCT05747794 Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy terminated 2026-06-30 Stop reason on the record: “Sponsor Decision” NCT05181462 Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. completed 2026-05-08 NCT05207709 Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype terminated 2026-03-26 Stop reason on the record: “The study was prematurely halted because enrollment was significantly delayed compared with the original projections due to the evolving therapeutic landscape.” NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT05963997 A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer completed 2026-03-06 NCT05063786 Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET) terminated 2025-12-23 Stop reason on the record: “Study prematurely terminated due to recruitment challenges, low incidence of the target population, evolving treatment landscape, ethical considerations, and inability to ensure funding through study ”	2026-06-30	29 NCT06324357 NCT06982521 NCT07413939 NCT05633654	78
9	Hospital Clinico Universitario de Valencia Valencia, Spain · 8 spellings merged	14 9 completed, 5 terminated	NCT05207709 NCT05180474 NCT05063786 6 trials with titles NCT05207709 Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype terminated 2026-03-26 Stop reason on the record: “The study was prematurely halted because enrollment was significantly delayed compared with the original projections due to the evolving therapeutic landscape.” NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT05063786 Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET) terminated 2025-12-23 Stop reason on the record: “Study prematurely terminated due to recruitment challenges, low incidence of the target population, evolving treatment landscape, ethical considerations, and inability to ensure funding through study ” NCT05963984 A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants completed 2025-08-28 NCT04603183 ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL completed 2025-06-30 NCT04224272 Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant completed 2025-06-30	2026-03-26	23 NCT06966453 NCT06393374 NCT06982521 NCT05633654	84
10	Hospital Universitario Ramón y Cajal Madrid, Spain · 12 spellings merged	14 9 completed, 5 terminated	NCT05207709 NCT05063786 NCT05520723 6 trials with titles NCT05207709 Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype terminated 2026-03-26 Stop reason on the record: “The study was prematurely halted because enrollment was significantly delayed compared with the original projections due to the evolving therapeutic landscape.” NCT05063786 Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET) terminated 2025-12-23 Stop reason on the record: “Study prematurely terminated due to recruitment challenges, low incidence of the target population, evolving treatment landscape, ethical considerations, and inability to ensure funding through study ” NCT05520723 Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED completed 2025-11-05 NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT05744375 Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab terminated 2025-07-17 Stop reason on the record: “The study stopped due to insufficient accrual (only two patients were included), and the sponsor has decided on its premature termination.” NCT04603183 ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL completed 2025-06-30	2026-03-26	21 NCT03424005 NCT06393374 NCT07413939 NCT06492616	83
11	Hospital Universitari Arnau de Vilanova Lleida, Spain · 7 spellings merged	13 8 completed, 5 terminated	NCT05181462 NCT05207709 NCT05063786 6 trials with titles NCT05181462 Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. completed 2026-05-08 NCT05207709 Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype terminated 2026-03-26 Stop reason on the record: “The study was prematurely halted because enrollment was significantly delayed compared with the original projections due to the evolving therapeutic landscape.” NCT05063786 Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET) terminated 2025-12-23 Stop reason on the record: “Study prematurely terminated due to recruitment challenges, low incidence of the target population, evolving treatment landscape, ethical considerations, and inability to ensure funding through study ” NCT05520723 Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED completed 2025-11-05 NCT05744375 Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab terminated 2025-07-17 Stop reason on the record: “The study stopped due to insufficient accrual (only two patients were included), and the sponsor has decided on its premature termination.” NCT04603183 ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL completed 2025-06-30	2026-05-08	8 NCT06982521 NCT05633654 NCT07174336 NCT04961996	86
12	City of Hope Duarte, United States · 16 spellings merged	13 6 completed, 7 terminated	NCT05325866 NCT05007106 NCT04699630 6 trials with titles NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT04699630 A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer completed 2025-04-09 NCT04539938 A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer completed 2025-03-07 NCT04737265 Pilot Study of an NTproBNP Guided Strategy of Cardioprotection completed 2025-02-05 NCT05070247 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors terminated 2025-01-06 Stop reason on the record: “Clinical Futility of TAK 500 met. No further development with this compound”	2026-01-28	37 NCT06058377 NCT03424005 NCT06966453 NCT06982521	86
13	Asan Medical Center Seoul, South Korea · 13 spellings merged	11 7 completed, 4 terminated	NCT05852691 NCT05325866 NCT06695039 6 trials with titles NCT05852691 A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer completed 2026-10-15 NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT06695039 Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in ER-positive Breast Cancer completed 2025-10-02 NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT04675827 De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade terminated 2024-11-26 Stop reason on the record: “Serious concerns on the slow recruitment of the study that impacts the robustness of the scientific rationale and the study financial provision. It aims to assess carefully the situation and to evalua” NCT04276493 Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab completed 2024-10-31	2026-10-15	37 NCT03424005 NCT06797635 NCT06393374 NCT06324357	85
14	Hospital Universitario San Cecilio Granada, Spain · 7 spellings merged	11 9 completed, 2 terminated	NCT06604858 NCT05181462 NCT05063786 6 trials with titles NCT06604858 Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer completed 2026-07-07 NCT05181462 Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. completed 2026-05-08 NCT05063786 Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET) terminated 2025-12-23 Stop reason on the record: “Study prematurely terminated due to recruitment challenges, low incidence of the target population, evolving treatment landscape, ethical considerations, and inability to ensure funding through study ” NCT05520723 Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED completed 2025-11-05 NCT05744375 Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab terminated 2025-07-17 Stop reason on the record: “The study stopped due to insufficient accrual (only two patients were included), and the sponsor has decided on its premature termination.” NCT06465368 A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause completed 2025-07-10	2026-07-07	16 NCT07413939 NCT05633654 NCT07174336 NCT07405801	92
15	Hospital Universitario HM Sanchinarro Madrid, Spain · 14 spellings merged	11 6 completed, 5 terminated	NCT05207709 NCT05180474 NCT06188559 6 trials with titles NCT05207709 Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype terminated 2026-03-26 Stop reason on the record: “The study was prematurely halted because enrollment was significantly delayed compared with the original projections due to the evolving therapeutic landscape.” NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT06188559 A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer completed 2026-03-18 NCT05063786 Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET) terminated 2025-12-23 Stop reason on the record: “Study prematurely terminated due to recruitment challenges, low incidence of the target population, evolving treatment landscape, ethical considerations, and inability to ensure funding through study ” NCT05896566 A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer completed 2025-09-18 NCT06465368 A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause completed 2025-07-10	2026-03-26	12 NCT03424005 NCT07174336 NCT04802759 NCT05086692	76
16	UPMC Hillman Cancer Center Pittsburgh, United States · 20 spellings merged	11 5 completed, 6 terminated	NCT06188559 NCT05554354 NCT04539938 6 trials with titles NCT06188559 A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer completed 2026-03-18 NCT05554354 Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) terminated 2025-04-04 Stop reason on the record: “Other - slow accrual” NCT04539938 A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer completed 2025-03-07 NCT04916002 A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer terminated 2024-10-31 Stop reason on the record: “Sponsor Decision related to study drug supply” NCT05259696 Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) completed 2024-10-24 NCT05383170 A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers completed 2024-09-23	2026-03-18	31 NCT06058377 NCT03424005 NCT03606967 NCT05633654	68
17	University of Wisconsin Carbone Cancer Center - University Hospital Madison, United States · 13 spellings merged	10 4 completed, 6 terminated	NCT04573231 NCT05554354 NCT04539938 6 trials with titles NCT04573231 Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer completed 2026-08-31 NCT05554354 Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) terminated 2025-04-04 Stop reason on the record: “Other - slow accrual” NCT04539938 A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer completed 2025-03-07 NCT04659603 Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors terminated 2025-01-19 Stop reason on the record: “Sponsor decision, the decision is not related to any safety concern.” NCT04849364 Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer terminated 2024-12-02 Stop reason on the record: “Funder Decision” NCT04588246 Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery terminated 2024-08-06 Stop reason on the record: “Inadequate accrual rate”	2026-08-31	31 NCT06058377 NCT06982521 NCT05633654 NCT06492616	81
18	Hospital Clinico San Carlos Madrid, Spain · 8 spellings merged	10 8 completed, 2 terminated	NCT05181462 NCT05963997 NCT05063786 6 trials with titles NCT05181462 Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. completed 2026-05-08 NCT05963997 A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer completed 2026-03-06 NCT05063786 Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET) terminated 2025-12-23 Stop reason on the record: “Study prematurely terminated due to recruitment challenges, low incidence of the target population, evolving treatment landscape, ethical considerations, and inability to ensure funding through study ” NCT05963984 A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants completed 2025-08-28 NCT04603183 ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL completed 2025-06-30 NCT04752332 A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer terminated 2024-06-26 Stop reason on the record: “Study is terminated due to inability to enroll study participants”	2026-05-08	15 NCT06393374 NCT06324357 NCT06982521 NCT06492616	84
19	Ohio State University Comprehensive Cancer Center Columbus, United States · 15 spellings merged	10 3 completed, 7 terminated	NCT05207709 NCT05554354 NCT04432454 6 trials with titles NCT05207709 Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype terminated 2026-03-26 Stop reason on the record: “The study was prematurely halted because enrollment was significantly delayed compared with the original projections due to the evolving therapeutic landscape.” NCT05554354 Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) terminated 2025-04-04 Stop reason on the record: “Other - slow accrual” NCT04432454 Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation completed 2025-01-28 NCT04916002 A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer terminated 2024-10-31 Stop reason on the record: “Sponsor Decision related to study drug supply” NCT04588246 Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery terminated 2024-08-06 Stop reason on the record: “Inadequate accrual rate” NCT04505826 A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer completed 2024-07-30	2026-03-26	43 NCT07391774 NCT06058377 NCT03424005 NCT03606967	60
20	Institut Curie Paris, France · 14 spellings merged	10 3 completed, 7 terminated	NCT05180474 NCT05963997 NCT05063786 6 trials with titles NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT05963997 A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer completed 2026-03-06 NCT05063786 Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET) terminated 2025-12-23 Stop reason on the record: “Study prematurely terminated due to recruitment challenges, low incidence of the target population, evolving treatment landscape, ethical considerations, and inability to ensure funding through study ” NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT06162351 A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer terminated 2025-05-15 Stop reason on the record: “No signal of significant toxicity and no signal of activity in the population of the TOPOLGY study” NCT06067061 "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer terminated 2025-05-07 Stop reason on the record: “insufficient recruitment”	2026-03-25	16 NCT06982521 NCT07174336 NCT06790693 NCT07898943	76
21	Institut Gustave Roussy Villejuif, France · 7 spellings merged	10 4 completed, 6 terminated	NCT05180474 NCT05325866 NCT05625087 6 trials with titles NCT05180474 GEN1047 for Solid Tumors - First in Human (FIH) Trial terminated 2026-03-25 Stop reason on the record: “The Sponsor has made a strategic decision to stop the development of GEN1047.” NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT05625087 Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib terminated 2026-01-20 Stop reason on the record: “poor accrual” NCT04725331 A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors terminated 2025-10-22 Stop reason on the record: “Sponsor decision following completion of Phase I part not driven by safety reason” NCT05896566 A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer completed 2025-09-18 NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05	2026-03-25	24 NCT03424005 NCT06324357 NCT06982521 NCT05633654	82
22	Texas Oncology - DFW Dallas, United States · 22 spellings merged	10 3 completed, 7 terminated	NCT05325866 NCT05383170 NCT05169437 6 trials with titles NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT05383170 A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers completed 2024-09-23 NCT05169437 Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors terminated 2024-08-27 Stop reason on the record: “Recruitment challenges” NCT04752332 A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer terminated 2024-06-26 Stop reason on the record: “Study is terminated due to inability to enroll study participants” NCT05113966 Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer terminated 2024-06-13 Stop reason on the record: “The Sponsor decided to close enrollment to the study on Feb 14, 2023, in order to reallocate resources to other ongoing trilaciclib clinical trials.” NCT04799249 Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC) completed 2024-05-24	2026-01-28	23 NCT06797635 NCT06966453 NCT06393374 NCT06982521	64
23	Seoul National University Hospital Seoul, South Korea · 19 spellings merged	9 5 completed, 4 terminated	NCT05852691 NCT05325866 NCT05007106 6 trials with titles NCT05852691 A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer completed 2026-10-15 NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT06465368 A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause completed 2025-07-10 NCT04675827 De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade terminated 2024-11-26 Stop reason on the record: “Serious concerns on the slow recruitment of the study that impacts the robustness of the scientific rationale and the study financial provision. It aims to assess carefully the situation and to evalua” NCT04276493 Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab completed 2024-10-31	2026-10-15	38 NCT03424005 NCT06797635 NCT06393374 NCT06324357	77
24	Severance Hospital, Yonsei University Health System Seoul, South Korea · 18 spellings merged	9 5 completed, 4 terminated	NCT05852691 NCT05325866 NCT05007106 6 trials with titles NCT05852691 A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer completed 2026-10-15 NCT05325866 A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression terminated 2026-01-28 Stop reason on the record: “Sponsor Decision” NCT05007106 MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) completed 2025-08-05 NCT06597175 Evaluating Investigational Medical Device for Breast Tumor Diagnosis Using Diffusion Optical Spectroscopy completed 2024-12-16 NCT04675827 De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade terminated 2024-11-26 Stop reason on the record: “Serious concerns on the slow recruitment of the study that impacts the robustness of the scientific rationale and the study financial provision. It aims to assess carefully the situation and to evalua” NCT04276493 Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab completed 2024-10-31	2026-10-15	38 NCT03424005 NCT06797635 NCT06393374 NCT06324357	78
25	Dana-Farber Cancer Institute Boston, United States · 8 spellings merged	9 3 completed, 6 terminated	NCT05573555 NCT05963997 NCT04539938 6 trials with titles NCT05573555 TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) terminated 2026-10-06 Stop reason on the record: “Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. The decision was not related to safety, efficacy, benefit-risk, or participant welfare. The pl” NCT05963997 A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer completed 2026-03-06 NCT04539938 A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer completed 2025-03-07 NCT05070247 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors terminated 2025-01-06 Stop reason on the record: “Clinical Futility of TAK 500 met. No further development with this compound” NCT04916002 A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer terminated 2024-10-31 Stop reason on the record: “Sponsor Decision related to study drug supply” NCT04505826 A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer completed 2024-07-30	2026-10-06	50 NCT05546268 NCT06324357 NCT06982521 NCT05315700	73

Investigators

Principal investigators and study chairs of the comparable trials, most trials first. Papers are matched on name, affiliation and condition; the match confidence is shown on each.

Breast cancer: principal investigators and study chairs of the comparable trials, with matched papers
#	Investigator	Comparable trials	Trials (ClinicalTrials.gov)	Papers (PubMed)
1	Antonio Llombart Arnau de Vilanova Hospital, Valencia (Spain)	5	NCT05659563 NCT04300790 NCT04464174 NCT04408118 NCT04240106	PMID 42567017 ESMO open, 2026 · High match PMID 42266036 The oncologist, 2026 · High match PMID 41647709 ESMO real world data and digital oncology, 2026 · High match
2	Zhongyu Yuan Sun Yat-sen University	4	NCT06533722 NCT05632848 NCT05300958 NCT04395339	PMID 42967914 Signal transduction and targeted therapy, 2026 · High match PMID 42963797 Breast cancer research : BCR, 2026 · High match PMID 42701446 Materials today. Bio, 2026 · High match
3	Alexander Philipovskiy Florida Cancer Specialists & Research Institute	4	NCT06257758 NCT05185947 NCT04570956 NCT04331067	No paper matched at High or Medium confidence
4	Aleix Prat Hospital Clínic of Barcelona / SOLTI	3	NCT05207709 NCT04578106 NCT04251169	PMID 42957778 Nature medicine, 2026 · High match
5	min yan Henan Cancer Hospital	3	NCT05394285 NCT05335473 NCT05176080	PMID 42933459 Lancet (London, England), 2026 · High match PMID 42925007 JAMA, 2026 · High match PMID 42897132 Signal transduction and targeted therapy, 2026 · High match
6	Rupert Bartsch Consultant Hematology and Medical Oncology, Medical University of Vienna	2	NCT05865990 NCT04752059	PMID 42986066 Journal of the National Cancer Institute, 2026 · High match PMID 42965829 Future oncology (London, England), 2026 · High match PMID 42927396 Breast care (Basel, Switzerland), 2026 · High match
7	Tomás Pascual Hospital Clínic of Barcelona / SOLTI cancer research group	2	NCT05207709 NCT04578106	PMID 42901050 ESMO open, 2026 · High match PMID 42602220 Therapeutic advances in medical oncology, 2026 · High match PMID 42567017 ESMO open, 2026 · High match
8	Norah L Henry University of Michigan Rogel Cancer Center	2	NCT06617455 NCT04754399	PMID 42931995 Breast cancer research and treatment, 2026 · High match PMID 42520859 International journal of radiation oncology, biology, physics, 2026 · High match PMID 42159636 Breast cancer research and treatment, 2026 · High match
9	Fei Ma National Cancer Center/Cancer Hospital, Peking Union Medical College	2	NCT06513364 NCT04892342	PMID 42965705 Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026 · High match PMID 42899250 Cancer innovation, 2026 · High match PMID 42888901 International journal of cancer, 2026 · High match
10	Antonio Llombart-Cussac Arnau de Vilanova Hospital, Valencia (Spain)	2	NCT04603183 NCT04714619	No paper matched at High or Medium confidence

How to read this

Sites are counted from the facility lists on the registry record, with spelling variants merged. “Listed on the trial” means the registry shows the site as a location; it is not a count of patients enrolled. The method, the formula and the published tests.

Want this for your own protocol or your CRO's list?

Leave your indication and the CRO's names. We reply by email with each one checked against these records.